Osteosarcoma biopsy: Difference between revisions

Jump to navigation Jump to search
(Mahshid)
 
(5 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Osteosarcoma}}
{{Osteosarcoma}}
{{CMG}};{{AE}} {{PSK}}
{{CMG}}; {{AE}}[[User:DrMars|Mohammadmain Rezazadehsaatlou[2]]].
==Overview==
==Overview==
Biopsy of osteosarcoma is important for confirming the diagnosis and the determining histologic subtype.<ref>Osteosarcoma. surgwiki. http://www.surgwiki.com/wiki/Diseases_of_bone_and_joints#SURGERY_4 </ref> Biopsy may be performed percutaneously with either a fine-needle, or wide-bore needle, or through a formal incision.
[[Biopsy]] of [[osteosarcoma]] is important for confirming the [[diagnosis]] and the determining histologic subtype. [[Biopsy]] may be performed [[percutaneously]] with either a [[Needle aspiration biopsy|fine-needle]], or wide-bore needle, or through a formal [[incision]].


==Biopsy==
==Biopsy==
*Biopsy of osteosarcoma is important for confirming the diagnosis and the determining histologic subtype.<ref>Osteosarcoma. surgwiki. http://www.surgwiki.com/wiki/Diseases_of_bone_and_joints#SURGERY_4 </ref>
*[[Biopsy]] of [[osteosarcoma]] is important for confirming the [[diagnosis]] and the determining [[Histology|histologic]] subtype.
*Biopsy may be performed percutaneously with either a fine-needle, or a wide-bore needle, or through a formal incision.
*[[Biopsy]] procedures include:<ref name="pmid25070231">{{cite journal |vauthors=Moore DD, Luu HH |title=Osteosarcoma |journal=Cancer Treat. Res. |volume=162 |issue= |pages=65–92 |date=2014 |pmid=25070231 |doi=10.1007/978-3-319-07323-1_4 |url=}}</ref><ref name="pmid20179183">{{cite journal |vauthors=Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M |title=Clinical presentation and imaging of bone and soft-tissue sarcomas |journal=Cleve Clin J Med |volume=77 Suppl 1 |issue= |pages=S2–7 |date=March 2010 |pmid=20179183 |doi=10.3949/ccjm.77.s1.01 |url=}}</ref><ref name="pmid21037356">{{cite journal |vauthors=Wu PK, Chen WM, Lee OK, Chen CF, Huang CK, Chen TH |title=The prognosis for patients with osteosarcoma who have received prior manipulative therapy |journal=J Bone Joint Surg Br |volume=92 |issue=11 |pages=1580–5 |date=November 2010 |pmid=21037356 |doi=10.1302/0301-620X.92B11.24706 |url=}}</ref><ref name="pmid29980176">{{cite journal |vauthors=Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M |title=The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients |journal=BMC Med. Genet. |volume=19 |issue=1 |pages=112 |date=July 2018 |pmid=29980176 |pmc=6035436 |doi=10.1186/s12881-018-0627-4 |url=}}</ref>  
*More invasive methods carry a higher risk of complications and contamination of tissue planes. Each year 30% of patients loose their limbs through inappropriate biopsy site and technique. In principle, biopsies should be performed at a tumor center by a specialist in tumor surgery.
**'''[[Needle biopsy]]'''
*Inappropriate alignment of the biopsy or inadvertent contamination of soft tissues can render subsequent limb-preserving reconstructive surgery impossible.
*** [[Percutaneously]] with either a [[Needle aspiration biopsy|fine-needle]], or a wide-bore needle
 
**'''Surgical biopsy'''
To view histopathologic characteristic features of all subtypes of osteosarcoma, click [[Osteosarcoma pathophysiology|'''here''']].
***Through a formal [[incision]]
*More [[invasive]] methods carry a higher risk of complications and contamination of tissue planes.  
*Each year 30% of patients lose their limbs through inappropriate [[biopsy]] site and technique.  
*In principle, [[Biopsy|biopsies]] should be performed at a tumor center by a specialist in tumor surgery.
*Inappropriate alignment of the [[biopsy]] or inadvertent contamination of [[soft tissue]]<nowiki/>s can render subsequent limb-preserving [[Reconstructive surgery|reconstructive]] surgery impossible.


==References==
==References==

Latest revision as of 13:20, 17 October 2019

Osteosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Osteosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Osteosarcoma biopsy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Osteosarcoma biopsy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Osteosarcoma biopsy

CDC on Osteosarcoma biopsy

Osteosarcoma biopsy in the news

Blogs on Osteosarcoma biopsy

Directions to Hospitals Treating Osteosarcoma

Risk calculators and risk factors for Osteosarcoma biopsy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammadmain Rezazadehsaatlou[2].

Overview

Biopsy of osteosarcoma is important for confirming the diagnosis and the determining histologic subtype. Biopsy may be performed percutaneously with either a fine-needle, or wide-bore needle, or through a formal incision.

Biopsy

References

  1. Moore DD, Luu HH (2014). "Osteosarcoma". Cancer Treat. Res. 162: 65–92. doi:10.1007/978-3-319-07323-1_4. PMID 25070231.
  2. Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M (March 2010). "Clinical presentation and imaging of bone and soft-tissue sarcomas". Cleve Clin J Med. 77 Suppl 1: S2–7. doi:10.3949/ccjm.77.s1.01. PMID 20179183.
  3. Wu PK, Chen WM, Lee OK, Chen CF, Huang CK, Chen TH (November 2010). "The prognosis for patients with osteosarcoma who have received prior manipulative therapy". J Bone Joint Surg Br. 92 (11): 1580–5. doi:10.1302/0301-620X.92B11.24706. PMID 21037356.
  4. Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M (July 2018). "The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients". BMC Med. Genet. 19 (1): 112. doi:10.1186/s12881-018-0627-4. PMC 6035436. PMID 29980176.

Template:WH Template:WS